Ola Landgren, MD, PhD, on Data From CARTITUDE-2 at 2021 ASCO

Ola Landgren, MD, PhD

Ola Landgren, MD, PhD, looks at results from the phase 2 CARTITUDE-2 trial of ciltacabtagene autoleucel for patients with multiple myeloma and 1 to 3 prior lines of therapy presented at the 2021 ASCO Annual Meeting.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Ola Landgren, MD, PhD, about data from the meeting that he thought was most likely to impact standard of care for patients with multiple myeloma. He cited data regarding the B-cell maturation antigen (BMCA)–targeting chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel) in patients with previously treated disease, which recently received FDA priority review for treatment of the indicated population.

Transcript:

There is so much going on in the myeloma field in 2021, so it’s hard to say which [research] has the strongest or highest clinical impact. I think there is impact every day and it’s changing constantly. Personally, I do think that the new updates for JNJ-4528 [cilta-cel] according to the CARTITUDE-2 trial [NCT04133636] are very exciting to see, [such] that a BCMA-targeted CAR T-cell [therapy] in patients with multiple myeloma who are heavily pretreated has a median duration close to 2 years. I think that’s very, very strong. I think that sends a message that cell therapy could have an important role for many patients.

But also, there was a lot of other activity. All the bispecific antibodies, there are presentations about that too. I’m sure we’ll hear even more details at the [American Society of Hematology Annual Meeting] in December 2021. They are coming with full speed. So how will the future look? We don’t know, but it’s going to look better and better, that’s for sure.

References

Agha ME, Cohen AD, Madduri D, et al. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. J Clin Oncol. 2021;39(suppl 15):8013. doi:10.1200/JCO.2021.39.15_suppl.8013